ARCT-030
Ornithine Transcarbamylase (OTC) Deficiency
PreclinicalResearch
Key Facts
Indication
Ornithine Transcarbamylase (OTC) Deficiency
Phase
Preclinical
Status
Research
Company
About Arcturus Therapeutics
Arcturus Therapeutics is a pioneer in mRNA therapeutics, leveraging its differentiated LUNAR® delivery and STARR™ self-amplifying mRNA platforms to create a diverse pipeline targeting infectious diseases, rare genetic disorders, and other therapeutic areas. The company achieved a major milestone with the approval and commercialization of its COVID-19 vaccine in Asia, validating its technology and establishing commercial capabilities. With strategic partnerships, including a major collaboration with CSL, Arcturus is advancing multiple clinical and preclinical programs while exploring the broad potential of its mRNA platform beyond vaccines.
View full company profileOther Ornithine Transcarbamylase (OTC) Deficiency Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed PRAM (OTC-targeting) | CAMP4 Therapeutics | Preclinical |
| ARCT-810 | Arcturus Therapeutics | Phase 1/2 |